Company Overview June 2018https://content.cdntwrk.com/files/aT05OTM2MjYmdj0xJmlzc3VlTmFtZT1wcm9tZXRpYy1jb3Jwb3JhdGUtb3ZlcnZpZXcmY21kPWQmc2lnPTk0MTUyMDUwODU1YzcxOGRkZWY1NDk1MzVjMWEyMTMy (from page 40)
Expected Milestones throughout 2018 – 2019
Small-Molecule Therapeutics Pipeline
PBI-4050 Initiation of IPF pivotal clinical trials
More data from on-going clinical trials (e.g. Alstrm Syndrome)
Expansion of the clinical program for Alstrm Syndrome
Series of peer reviewed publications on MoA and efficacy
Partnering of selected indications and/or geographies
PBI-4547
To enter clinical phase IVIG
Completion of Phase 1
Initiation of Phase 2 studies (NASH and / or Orphan indication)
PBI-4425
To enter clinical phase
Plasma-derived Therapeutics Pipeline
PLASMINOGEN
Commercial launch in the USA & Canada
Priority Review Voucher - monetization
Grant of additional Orphan Drug Designations
New data for future use in critical medical conditions
Preliminary read-out clinical data for Diabetic Foot Ulcer
Preliminary read-out clinical data for TMP Repair
Partnering for selected indications and geographies
IVIG
Completion of Phase III in paediatric patients
Filing of BLA for the USA & Canada
INTER ALPHA 1
Preparation for clinical program following
Orphan Drug & Rare Paediatric Designations granted for NEC